Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis

Journal of Rheumatology

Volumn 25, Issue 2, 1998, Pages 302-307

  Seibold, James R ^a,i   Clements, Philip J ^b   Furst, Daniel E ^c   Mayes, Maureen D ^d   McCloskey, Deborah A ^a   Moreland, Larry W ^e   White, Barbara ^f   Wigley, Fredrick M ^g   Rocco, Susan ^h   Erikson, Mark ^h   Hannigan, John F ^h   Sanders, Martin E ^h   Amento, Edward P ^h  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Palo Alto Institute of Molecular Medicine   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Fibrosis; Relaxin; Systemic sclerosis

Indexed keywords

HEMOGLOBIN; RECOMBINANT RELAXIN; RELAXIN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; INJECTION PAIN; MALE; PRIORITY JOURNAL; RASH; SCLERODERMA; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 6844266294     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Schwabe C, Bullesbach EE. Relaxin structure and function. In: MacLennan AH, Tregear GW, Bryant-Greenwood GD, editors. Progress in relaxin research. Singapore: World Scientific Publishing; 1995:43-58.
2. Sherwood OD. Relaxin. In: Knobel E, Neill J, editors. The physiology of reproduction. New York, Raven Press; 1988:585-673.
3. Noble N, Boucek R. Hormonal effects upon in vivo cholesterol synthesis. Circulation Res 1957;5:573-7.
4. Steinetz BG, Kroc RL, Greep RO. An historical perspective on relaxin. In: MacLennan AH, Tregear GW, Bryant-Greenwood GD, editors. Progress in relaxin research. Singapore: World Scientific Publishing; 1995:3-27
5. Casten GG, Boucek RJ. Use of relaxin in the treatment of scleroderma. JAMA 1958;166:319-24.
6. Vandlen R, Winslow J, Moffat B, Rinderknecht E. Human relaxin: purification, characterization and production of recombinant relaxin for structure function studies. In: MacLennan AH, Tregear GW, Bryant-Greenwood GD, editors. Progress in relaxin research. Singapore: World Scientific Publishing; 1995:59-72.
7. Unemori EN, Bauer EA, Amento EP. Relaxin alone and in conjunction with interferon decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol 1992;99:337-42.
8. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 1990;265:10681-5.
9. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996;98:2739-45.
10. Unemori EN, Beck S, Lee WP, et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 1993;101:280-5.
11. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
12. Clements P, Lachenbruch P, Seibold JR, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
13. Seibold JR, Furst DE, Clements P. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 1992;19:673-6.
14. Steen VD, Conte C, Day N, Ramsey-Goldman R, Medsger TA. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989;32:151-7.
15. Pope JE, Baron ME, Bellamy N, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol 1995;22:1271-6.
16. Kahn CR, Shechter Y. Insulin, oral hypoglycemic agents, and the pharmacology of the exocrine pancreas. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacologic basis of therapeutics, 8th ed. New York: Pergamon; 1990:1463-95.
17. White B. Pathogenesis: immune aspects. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996:229-50.
18. Seibold JR. Scleroderma. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology, 5th ed. Philadelphia: WB Saunders; 1997:1133-62.
19. Seibold JR, Furst DE, Clements PJ. Treatment of systemic sclerosis by disease modifying agents. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996:535-48.
20. Bigazzi M, Bani D, Bani G, Sacchi TB. Relaxin and the cardiocirculatory system. In: MacLennan AH, Tregear GD, Bryant-Greenwood GD, editors. Progress in relaxin research. Singapore: World Scientific Publishing; 1995:499-512.
21. Lane B, Oxyberry W, Mazella J, Tseng L. Decidualization of human endometrial stromal cells in vitro: effects of progestin and relaxin on the ultrastructure of endometrial stromal cells in culture. Hum Reprod 1994;9:259-66.